Core Viewpoint - Zhongju Gaoxin reported a significant increase in third-quarter profits, attributed to a decrease in raw material prices and increased sales, despite facing substantial losses in the first three quarters due to a major lawsuit related to land use rights [1][2]. Financial Performance - For the first nine months of 2023, Zhongju Gaoxin achieved a total revenue of 3.953 billion yuan, a slight decrease of 0.08% year-on-year, while the net profit attributable to the parent company was a loss of 1.272 billion yuan, a decrease of 1.691 billion yuan, representing a decline of 403.89% [2]. - In the third quarter, the company reported a net profit of approximately 170 million yuan, marking a year-on-year increase of about 60% [2]. Legal Issues - The significant losses in the first three quarters were primarily due to a lawsuit regarding land use rights, which resulted in a provision for expected liabilities of 1.747 billion yuan [2][3]. - The lawsuit is seen as part of the ongoing power struggle between the Baoneng and Huojun factions, with the Huojun faction seeking to reclaim control over Zhongju Gaoxin [3]. Management Changes - Zhongju Gaoxin appointed several executives with backgrounds in the China Resources Group, including Yu Xiangyang as General Manager and Lin Ying as Executive Vice General Manager [4]. - The appointments were made following recommendations from major shareholders, particularly the Huojun faction, and there are currently no business collaborations planned with China Resources [4]. Shareholding Structure - The Huojun faction, along with its allies, holds a combined 19.65% stake in Zhongju Gaoxin, surpassing the Baoneng faction [6]. - The Baoneng faction is facing a judicial auction of 6 million shares, which will further reduce its stake in the company [6]. Audit Firm Change - Zhongju Gaoxin plans to change its auditing firm from Lixin Certified Public Accountants to Tianzhi International Certified Public Accountants, which previously served the company for 18 consecutive years from 2001 to 2018 [7].

Group 1 - ST Unimed (002581.SZ) announced a settlement with Hangzhou Qiangxin Biotechnology Co., resolving a previous equity dispute regarding the 34% stake of its subsidiary, Xiamen Unimed [2][4] - The dispute involved the former chairman of Unimed, Pan Aihua, and Hangzhou Qiangxin's legal representative, Li Pengfei, who were sentenced to several years in prison in February 2024 [2][3] - Hangzhou Qiangxin agreed to transfer the 34% stake in Xiamen Unimed back to Unimed without compensation, while Unimed expressed understanding towards Li Pengfei's alleged embezzlement [2][4] Group 2 - The equity dispute began in May 2022 when Pan Aihua, facing debt issues, signed a deal allowing Hangzhou Qiangxin to acquire the 34% stake for approximately 2.9 billion yuan, which led to a change in control over Xiamen Unimed [3][5] - Unimed later discovered that the 2.9 billion yuan investment by Hangzhou Qiangxin had not been received, and the acquisition was made through an increase in registered capital without actual payment [4] - The court ruled that Hangzhou Qiangxin must return the 34% stake to Unimed, while the criminal responsibilities of the involved parties are still under judicial review [4][5]